Radioimmunotherapy combined with maintenance anti-CD20 antibody may trigger long-term protective T cell immunity in follicular lymphoma patients

7Citations
Citations of this article
16Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Growing evidence suggests that the patient's immune response may play a major role in the long-term efficacy of antibody therapies of follicular lymphoma (FL). Particular long-lasting recurrence free survivals have been observed after first line, single agent rituximab or after radioimmunotherapy (RIT). Rituximab maintenance, furthermore, has a major efficacy in prolonging recurrence free survival after chemotherapy. On the other hand, RIT as a single step treatment showed a remarkable capacity to induce complete and partial remissions when applied in recurrence and as initial treatment of FL or given for consolidation. These clinical results strongly suggest that RIT combined with rituximab maintenance could stabilize the high percentages of patients with CR and PR induced by RIT. While the precise mechanisms of the long-term efficacy of these 2 treatments are not elucidated, different observations suggest that the patient's T cell immune response could be decisive. With this review, we discuss the potential role of the patient's immune system under rituximab and RIT and argue that the T cell immunity might be particularly promoted when combining the 2 antibody treatments in the early therapy of FL. © 2013 Franz Buchegger et al.

References Powered by Scopus

Improved survival with ipilimumab in patients with metastatic melanoma

12782Citations
N/AReaders
Get full text

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

10554Citations
N/AReaders
Get full text

Nivolumab plus Ipilimumab in advanced melanoma

3606Citations
N/AReaders
Get full text

Cited by Powered by Scopus

A molecular perspective on rituximab: A monoclonal antibody for B cell non Hodgkin lymphoma and other affections

65Citations
N/AReaders
Get full text

Aptamers as quality control tool for production, storage and biosimilarity of the anti-CD20 biopharmaceutical rituximab

24Citations
N/AReaders
Get full text

Impact of depleting therapeutic monoclonal antibodies on the host adaptive immunity: A bonus or a malus?

11Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Buchegger, F., Larson, S. M., Mach, J. P., Chalandon, Y., Dietrich, P. Y., Cairoli, A., … Speiser, D. E. (2013). Radioimmunotherapy combined with maintenance anti-CD20 antibody may trigger long-term protective T cell immunity in follicular lymphoma patients. Clinical and Developmental Immunology. https://doi.org/10.1155/2013/875343

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 7

70%

Researcher 2

20%

Professor / Associate Prof. 1

10%

Readers' Discipline

Tooltip

Medicine and Dentistry 10

71%

Agricultural and Biological Sciences 2

14%

Veterinary Science and Veterinary Medic... 1

7%

Engineering 1

7%

Save time finding and organizing research with Mendeley

Sign up for free